AstraZeneca Court Ruling Means All Six of HRSA’s 340B Original Contract Pharmacy Violation Letters are Dead

Yesterday’s court decision in AstraZeneca’s 340B contract pharmacy lawsuit made the final score 6-0 in favor of drug manufacturers in their fight with the federal government over the legality of its May 17, 2021, letters telling Astra, Lilly, Novartis, Novo Nordisk, Sanofi, and United Therapeutics that their actions have resulted in overcharges and are in direct violation of the 340B statute.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

AstraZeneca Court Ruling Means All Six of HRSA’s 340B Original Contract Pharmacy Violation Letters are Dead

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Tom Mirga